Drug repositioning platform for central nervous system diseases
Equity 1 : 349 000€
Equity 2 : 750 000€
Année :
2023
Nadine Mackenzie
Rheumatologist, Medical Director in the pharmaceutical industry for 20 years, and former member of the Executive Committee of LEO Pharma France.
Pourquoi Valeureux a investi ?
A rare opportunity to take part in the development of a capital-light biotech, thanks to its drug repositioning strategy. Its Parkinson's hit will already be in clinical Phase II within an 18-month horizon.
By clicking on “Accept all cookies”, you agree that cookies may be stored on your device in order to improve site navigation, analyze site usage, and help us with our marketing efforts.
